REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
15/06/2026
Voltar para busca
Dado oficial do USPTO
ITM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
16/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 42, 44
Data de depósito
28/07/2020
Data de registro
15/06/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/06/2021
Última transação
16/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
25
Localização do titular
DE
Examinador
BHUPATHI, TARA
Unidade examinadora
N60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of "ITM" in stylized form with two circles emanating from the left corner of the "I" in "ITM" at a diagonal.
Titulares e representantes
Titulares
I. S. (pessoa física)
ITM Isotopen Technologien München AG
Representantes
Kari Moyer-Henry Lewis Kohn & Walker LLP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposesin particular radiopharmaceutical preparations for endo-radionuclide therapybrachytherapy and radiopharmaceutical preparations for positron emission tomography PET or single photon emission tomography SPECTtarget radionuclide and peptide receptor radionuclide therapy PRRT; theranostics in the field of precision oncology; radiopharmaceutical productslutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncologyradiopharmaceuticals containing radioisotopese.g. lutetium-177actinium-225yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target moleculee.g. peptide or antibodydepending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexesgallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin GEP-NET; radiopharmaceuticals for use in the therapy of GEP-NETosteosarcomabone metastasesprostate cancerbreast cancerbrain cancerovarian cancer; radiopharmaceuticals containing radioisotopes with short half-livessuch as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET positron emission tomography or SPECT single photon emission tomographyfor the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-livesin particular lutetium-177actinium-225 or yttrium-90 for the treatment of tumour diseases
Classe 10
Medical instrumentsapparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controllingregulating and measuring apparatus as parts of medical instrumentsapparatus and containers included in this classin particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes
Classe 42
Conducting clinical trials for others at all stages and in various indicationsparticularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin GEP-NET
Classe 44
Medical servicesin particular services relating to radiotherapeutic and radiodiagnostic oncologycardiologyangiologyneuroradiology and nuclear medicine and brachytherapiesincluding intercavitaryinterstitial and intravascular brachytherapyradionuclide labellingPET and SPECT scanning and target radionuclide therapypeptide receptor radionuclide therapy PRRTpersonal nuclear medicine and precision oncology
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
26/11/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/11/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/10/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
30/09/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
30/09/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/09/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
15/06/2021
GPNX
NOTIFICATION PROCESSED BY IB
05/04/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/03/2021
PUBO
PUBLISHED FOR OPPOSITION
30/03/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/03/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
23/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
23/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
23/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
23/02/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/02/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/02/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/02/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/02/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/02/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/02/2021
RFNT
REFUSAL PROCESSED BY IB
27/12/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/12/2020
RFRR
REFUSAL PROCESSED BY MPU
08/12/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/11/2020
CNRT
NON-FINAL ACTION WRITTEN
19/11/2020
DOCK
ASSIGNED TO EXAMINER
16/11/2020
MAFR
APPLICATION FILING RECEIPT MAILED
23/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ITM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.